MHC

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Tuesday, April 9, 2024
Major histocompatibility complex, CPI, Cell, Entrepreneurship, Oncology, Immunotherapy, DLL4, Patient, Neoplasm, Data, Tumor microenvironment, VEGF, Checkpoint, Doctor of Philosophy, MD, Natural killer T cell, News, AACR, MHC, Research and development, Therapy, MHC-I, Antibody, Immune system, PD-L1, San Diego Convention Center, NK, PD-1, Vaccine

Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471.

Key Points: 
  • Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471.
  • The proposed mechanism for this effect suggests the involvement of NK-cells, which can generate potent cell killing independent of MHC-I.
  • Following mCTX-009 and mCTX-471 combination treatment, superior efficacy was observed in MHC Class I negative tumors.
  • A copy of the presentation materials can be accessed on the News & Events section under “ Presentations ” of the Company’s website at www.compasstherapeutics.com once the presentation has concluded.

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

Retrieved on: 
Friday, March 29, 2024
Multiple myeloma, Private placement, Symantec Endpoint Protection, EGFR, CD8, Exercise, Disease, AML, HNSCC, CMV, Patient, Common, Tom Clancy's Ghost Recon, Neoplasm, Immunoglobulin A, Tumor microenvironment, Sale, Bristol Myers Squibb, Form 10-K, Cancer, MHC, PD-L1, Antibody, Interim, Therapy, MTD, Poster, Total, ETB, UPR, Pharmaceutical industry

The net loss attributable to common shareholders for the fourth quarter of 2023 was $3.9 million, or $0.73 per basic and diluted share.

Key Points: 
  • The net loss attributable to common shareholders for the fourth quarter of 2023 was $3.9 million, or $0.73 per basic and diluted share.
  • Revenues for the fourth quarter of 2023 were $7.0 million, compared to $2.6 million for the same period in 2022.
  • Revenues for the fourth quarter of 2023 were comprised of revenues from collaborative research and development agreements with Bristol-Myers Squibb and grant revenue.
  • For more details on MTEM’s financial results for 2023, refer to Form 10-K filed with the SEC.

AbCellera Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024

Retrieved on: 
Monday, April 8, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Toxicity, 5T4, Translational research, Autoimmunity, Risk, Trichloroethylene, SVP, Cancer, Protein, CD3, Translation, AACR, Doctor of Philosophy, MHC, ABCL, TCE, Safety, CD28, San Diego Convention Center, PSMA, Peptide, Pharmaceutical industry

Together, AbCellera’s data demonstrate that it is well-positioned to advance TCEs as a drug class by widening the therapeutic window, enhancing potency, and broadening the accessible target space.

Key Points: 
  • Together, AbCellera’s data demonstrate that it is well-positioned to advance TCEs as a drug class by widening the therapeutic window, enhancing potency, and broadening the accessible target space.
  • “Our data illustrate that we can repeatedly generate TCEs that maximize tumor-cell killing without inducing excessive cytokine release.
  • The data show that AbCellera’s IgG and heavy chain-only CD28-binding antibodies do not display superagonist activity — a property associated with toxicity.
  • “We look forward to advancing these programs with the aim of delivering powerful new medicines for patients.”

CFSB BANCORP, INC. ANNOUNCES ADOPTION OF REPURCHASE PROGRAM

Retrieved on: 
Friday, April 5, 2024
MHC, Security (finance)

This is the Company's first stock repurchase program since completing its mutual holding company reorganization and related stock offering in January 2022.

Key Points: 
  • This is the Company's first stock repurchase program since completing its mutual holding company reorganization and related stock offering in January 2022.
  • Repurchases are expected to commence after the Company publicly releases its results of operations for the period ended March 31, 2024.
  • Open market purchases will be made in accordance with Rule 10b-18 of the Securities and Exchange Commission and other applicable legal requirements.
  • The Company is not obligated to repurchase any particular number of shares or any shares in any specific time period.

Dassault Systèmes and CDR-Life Collaborate to Accelerate Scientific Innovation for Cancer Therapies

Retrieved on: 
Tuesday, March 12, 2024
Manufacturing, Environment, Research, Oncology, Software, Finance, Medical Devices, Hardware, Electronic Design Automation, Data Management, Professional Services, Science, Technology, Data Analytics, Biotechnology, Other Manufacturing, Health, Engineering, Healthcare industry, Risk, Hospital, 3D, Cancer, Dassault Group, Product lifecycle, BIOVIA, MHC, Immune system, Euronext Paris, Probability, PLM, Vaccine

Scientists from Dassault Systèmes’ Contract Research team worked closely with scientists from CDR-Life to perform virtual “what if” experiments on antibody-based biologics called T-cell engagers, using Dassault Systèmes’ BIOVIA software and CDR-Life’s experimental data.

Key Points: 
  • Scientists from Dassault Systèmes’ Contract Research team worked closely with scientists from CDR-Life to perform virtual “what if” experiments on antibody-based biologics called T-cell engagers, using Dassault Systèmes’ BIOVIA software and CDR-Life’s experimental data.
  • “Our collaboration with Dassault Systèmes’ Contract Research team accelerated our research and development efforts based on our proprietary antibody-based MHC-targeting T-cell engager technology.
  • Pharmaceutical and biotechnology companies of all sizes seek to accelerate the development of therapies that will help people live healthier lives,” said Claire Biot, Vice President, Life Sciences & Healthcare Industry, Dassault Systèmes.
  • Dassault Systèmes’ 3DEXPERIENCE platform, 3D design software, 3D Digital Mock Up and Product Lifecycle Management (PLM) solutions: http://www.3ds.com
    M-gager is a proprietary technology and registered trademark of CDR-Life.

XtalPi to Present the Latest Progress of Its AI Cancer Vaccine Design Platform at AACR 2024

Retrieved on: 
Thursday, March 28, 2024
TP53, Innovation, Innovation Center station, Patient, Surface plasmon resonance, Artificial intelligence, Cancer, Allele, HLA, CK Life Sciences, AACR, Robotics, MHC, MHC-II, Therapy, Cosmetics, Data, Probability, Peptide, Vaccine

The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.

Key Points: 
  • The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.
  • "We are excited to share the progress from our joint research initiative with CK Life Sciences, which leverages the innovative approach from our peptide R&D platform to design cancer vaccines with enhanced efficacy.
  • Our developed AI models surpassed the performance of state-of-the-art prediction algorithms, the latest versions of NetMHCpan and MixMHCpred, for both MHC-I and MHC-II antigen presentation.
  • The peptide R&D platform can carry out high-precision AI peptide design and has successfully built data-driven design processes for both linear and cyclic peptides.

XtalPi to Present the Latest Progress of Its AI Cancer Vaccine Design Platform at AACR 2024

Retrieved on: 
Thursday, March 28, 2024
TP53, Innovation, Innovation Center station, Patient, Surface plasmon resonance, Artificial intelligence, Cancer, Allele, HLA, CK Life Sciences, AACR, Robotics, MHC, MHC-II, Therapy, Cosmetics, Data, Probability, Peptide, Vaccine

The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.

Key Points: 
  • The meeting will take place from 5th – 10th April 2024 in San Diego, California, and XtalPi's poster will be included in the online Proceedings of the AACR.
  • "We are excited to share the progress from our joint research initiative with CK Life Sciences, which leverages the innovative approach from our peptide R&D platform to design cancer vaccines with enhanced efficacy.
  • Our developed AI models surpassed the performance of state-of-the-art prediction algorithms, the latest versions of NetMHCpan and MixMHCpred, for both MHC-I and MHC-II antigen presentation.
  • The peptide R&D platform can carry out high-precision AI peptide design and has successfully built data-driven design processes for both linear and cyclic peptides.

Matterport Announces Fourth Quarter and Full Year 2023 Financial Results Demonstrating Strong Recurring Revenue Growth and Reaffirms 2024 Profitability Target

Retrieved on: 
Tuesday, February 20, 2024
Cloud, International, Collection, Vacasa, Marketing, Real estate, Music, Student, University, Property, Investment, Construction, Partnership, Biophysical environment, Facility management, ESG, Resort, Travel, Facility, Crave, 3D camera, MHC, Video game

“We closed 2023 on a high note with fourth quarter total revenue of $39.5 million, in line with our guidance range.

Key Points: 
  • “We closed 2023 on a high note with fourth quarter total revenue of $39.5 million, in line with our guidance range.
  • Subscription revenue growth accelerated to 23% year-over-year, ahead of our expectations, driven by broad based strength across our global customer base.
  • This launch sets the stage for 2024 to be the year of the intelligent digital twin, fueling our AI-driven revenue growth and accelerating us towards our profitability goal,” Pittman added.
  • The Company is providing the following financial guidance for the first quarter and full year 2024.

TFS Financial Corporation Declares Dividend

Retrieved on: 
Thursday, February 22, 2024
Banking, Professional Services, Finance, Love, Federal Reserve Bank, Multimedia, Annual report, News, TFS, The Association, Security (finance), Trust, MHC, Third Federal S&L

TFS Financial Corporation (NASDAQ: TFSL) (the "Company"), the holding company for Third Federal Savings and Loan Association of Cleveland (the "Association"), today announced that the Board of Directors declared a quarterly cash dividend of $0.2825 per share, payable on March 21, 2024, to stockholders of record on March 7, 2024.

Key Points: 
  • TFS Financial Corporation (NASDAQ: TFSL) (the "Company"), the holding company for Third Federal Savings and Loan Association of Cleveland (the "Association"), today announced that the Board of Directors declared a quarterly cash dividend of $0.2825 per share, payable on March 21, 2024, to stockholders of record on March 7, 2024.
  • Founded in Cleveland in 1938 as a mutual association by Ben and Gerome Stefanski, Third Federal's mission is to help people achieve the dream of home ownership and financial security.
  • It became part of a public company in 2007 and celebrated its 85th anniversary in May 2023.
  • These forward-looking statements involve risks and uncertainties that could cause the Company's results to differ materially from management's current expectations.

CureIS and MHC Services Group Announce Partnership

Retrieved on: 
Wednesday, February 21, 2024
Automation, MHC, Partnership

WOODBURY, Minn., Feb. 21, 2024 /PRNewswire/ -- CureIS Healthcare, Inc. and MHC Services Group today announced their partnership providing a dynamic team of problem-solvers who take accountability to the next level in their mission to deliver clean, quality healthcare data to health plans and other at-risk entities.

Key Points: 
  • WOODBURY, Minn., Feb. 21, 2024 /PRNewswire/ -- CureIS Healthcare, Inc. and MHC Services Group today announced their partnership providing a dynamic team of problem-solvers who take accountability to the next level in their mission to deliver clean, quality healthcare data to health plans and other at-risk entities.
  • "We are excited about our partnership with MHC and the powerful solutions we collectively bring to the industry.
  • We are thrilled to work closely with the CureIS team and align our professional service specialties with CureIS's technology experts to provide innovative and affordable solutions to our clients" said Graham Higton, MHC Services Group, President.
  • CureIS and MHC are healthcare industry experts driven to improve healthcare operations with analytical and interpretative services combined with healthcare-focused automation technology that consumes, analyzes, and improves data, in any format, from any source.